Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Core Insights - Arrowhead Pharmaceuticals has transitioned into a commercial-stage organization following the FDA approval of its first medicine, REDEMPLO (plozasiran), marking a significant strategic turning point [1] - The company reported a substantial increase in revenue and net income for FQ1 2026, driven by collaborations with Novartis and Sarepta Therapeutics [4] Group 1: Company Developments - Arrowhead achieved over 100 initial prescriptions for REDEMPLO in the US and established a dedicated patient support program [2] - The company initiated a Phase 1/2a trial for ARO-DIMER-PA, the first dual-function clinical candidate targeting two genes in one molecule [2] - Arrowhead reported positive interim data from its obesity programs, particularly with ARO-INHBE showing significant weight loss when combined with tirzepatide [2] Group 2: Financial Performance - Arrowhead's revenue for FQ1 2026 reached $264 million, a significant increase compared to the previous year [4] - The company reported a net income of $30.8 million for the quarter, contrasting sharply with a loss of $173.1 million in the same period last year [4] - The revenue surge was attributed to a $200 million upfront payment from a collaboration with Novartis and a $200 million milestone payment from Sarepta Therapeutics [4] Group 3: Product Pipeline - Arrowhead's pipeline includes key products such as Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3, focusing on treatments for intractable diseases [5]